Faruqi & Faruqi, LLP is investigating claims on behalf of investors in Anavex

NEW YORK, May 10, 2024 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating and reminds investors of potential claims against Anavex Life Sciences Corporation (“Anavex” or the “Company”) (NASDAQ: AVXL). May 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.

James (Josh) Wilson, Faruqi and Faruqi, LLP Securities Litigation Partner, encourages investors who have suffered losses that are greater $75,000 In Anavex you can contact him directly to discuss your options

If you have suffered losses that go beyond this $75,000 Investing in Anavex stocks or options in between June 21, 2021 And January 1, 2024 and would like to discuss your legal rights, Call Faruqi & Faruqi Partners Josh Wilson direct at 877-247-4292 or 212-983-9330 (ext. 1310). For more information you can also click here: www.faruqilaw.com/AVXL.

Faruqi & Faruqi is a leading national securities law firm with offices in new York, Pennsylvania, California And Georgia. The company has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

The complaint claims that on December 2, 2022AVXL announced positive sales results for its phase 2 B/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) . ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 as well as the key secondary endpoint CDR-SB3 with statistically significant results. One analyst questioned the company’s claim, noting: “There are several key factors that lead us to believe that the data is provocative but not yet convincing, given the choice of statistical analysis and other ‘complexifiers’ for study design.” In addition, a biotech journalist commented on AVXL’s findings by saying, “What sets Anavex apart from all the other biotech companies on my radar screen is its habit of moving the goalposts on clinical trials… Anavex stated ” “positive” results from studies of its drug known as blarcamesine – except that the results were derived from efficacy endpoints that were not part of the original study design.”

At January 2, 2024, the company announced the results of the Excellence Study. To analyze the data, the company used the “MMRM” method – a statistical method not used in the Avatar study. Excellence failed to reach statistical significance for all but one measure. According to the complaint, Anavex’s stock price fell more than 35% on this news.

The court-appointed lead plaintiff is the investor with the greatest financial interest in the relief sought by the class, who is appropriate and typical of the class, and who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may request the Court to serve as lead plaintiff through counsel of their choice, or may elect to do nothing and remain an absent class member. Your ability to share in any recovery will not be affected by the decision to serve as lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information about Anavex’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

To find out more about the Anavex Class action lawsuit, go for it www.faruqilaw.com/AVXL or Call Faruqi & Faruqi Partners Josh Wilson direct at 877-247-4292 or 212-983-9330 (ext. 1310).

Lawyer advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar result with respect to future matters. We welcome the opportunity to discuss your individual case. All communications will be treated confidentially.

SOURCE Faruqi & Faruqi, LLP